Antidepressant Use in Pregnancy: Side Effects, Safety, and What the Data Really Shows

The Real Risk: Untreated Depression vs. Medication

We need to flip the script on how we talk about this. Most people focus on what the pill might do to the baby, ignoring what the disease does to both mother and child. Untreated depression is not just sadness; it is a medical condition with physical consequences. According to the Society for Maternal-Fetal Medicine (SMFM), depression affects roughly 14.5% of pregnant individuals in the U.S. If left unmanaged, it raises the risk of preterm birth by 40%, low birth weight by 30%, and preeclampsia by 25%.

The stakes are even higher for the mother. Mental health conditions are now the leading cause of pregnancy-related death in the United States, accounting for nearly a quarter of all such deaths between 2017 and 2019. A 2024 cohort study tracking nearly 1 million women found that untreated depression triples the risk of suicidal behavior. When you weigh those numbers against the side effects of medication, the choice becomes clearer for many patients. The goal isn't just a healthy baby; it's a safe, stable environment for that baby to grow in.

SSRIs: The Gold Standard for Pregnancy

When doctors prescribe antidepressants during pregnancy, they almost always reach for Selective Serotonin Reuptake Inhibitors, or SSRIs. These drugs have been around since the late 1980s, meaning we have decades of safety data. They work by increasing serotonin levels in the brain, which helps regulate mood. Among SSRIs, Sertraline (Zoloft) and Citalopram (Celexa) are generally considered first-line treatments. Why? Because they have the most extensive safety records and lower rates of transfer across the placenta compared to older drugs.

You might hear about other classes like SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) or Tricyclic Antidepressants. While these can be effective, SSRIs are preferred because their side effect profile is better understood in the context of pregnancy. The key takeaway is consistency. If you were already on an SSRI before getting pregnant and it was working, switching medications introduces new variables and potential withdrawal symptoms. Stability is usually the best policy.

The Paroxetine Exception: Know Your Drug

Not all antidepressants are created equal when it comes to pregnancy. Paroxetine (Paxil) stands out as a significant exception. Unlike other SSRIs, paroxetine has been linked to a higher risk of congenital heart defects. Studies show a 1.5 to 2.0-fold increased risk of cardiac issues compared to other SSRIs. If you are currently taking Paxil, this is the one scenario where switching medications before conception-or immediately upon discovering pregnancy-is strongly recommended. Talk to your psychiatrist about transitioning to sertraline or citalopram. This specific risk is why knowing your exact medication name matters so much.

Busting the Birth Defect Myth

For years, headlines screamed that antidepressants caused birth defects. The reality is much more nuanced. Early studies suggested a slight increase in major congenital malformations, but those studies suffered from "indication bias." They compared women taking antidepressants to women who were perfectly mentally healthy, ignoring the fact that the underlying depression itself carries risks.

When researchers controlled for this-comparing depressed women on medication to depressed women without medication-the link to birth defects disappeared. A 2018 meta-analysis by Gao et al. showed that when restricted to women with psychiatric diagnoses, the odds ratio for major anomalies dropped to 1.04, which is statistically negligible. In July 2025, the SMFM issued a statement emphasizing that available data consistently show SSRI use is not associated with congenital anomalies, fetal growth problems, or long-term developmental issues. The fear of birth defects is largely based on outdated or poorly adjusted data.

Neonatal Adaptation Syndrome: What to Expect

If you continue your medication through the third trimester, there is one side effect you should be prepared for: Neonatal Adaptation Syndrome (PNAS). About 30% of infants exposed to SSRIs near delivery may experience transient symptoms. These aren't permanent damages; they are temporary adjustments. Symptoms can include jitteriness, mild respiratory distress, poor feeding, or irritability.

These symptoms typically resolve within two weeks without long-term consequences. It’s crucial to tell your pediatrician and labor team that you are on an SSRI so they can monitor the baby closely right after birth. Knowing this is coming helps reduce panic. It is a known, manageable reaction, not a hidden danger. The hospital staff will know exactly how to support both you and the baby during this short transition period.

The Danger of Stopping Cold Turkey

Perhaps the most common mistake is abrupt discontinuation. Many women stop their meds as soon as they get a positive test, fearing any exposure is bad. This is a dangerous gamble. Studies show that 68% of pregnant women who discontinue antidepressants experience a relapse of depression, compared to only 26% who stay on the medication. Relapse doesn't just hurt you; it disrupts prenatal care, nutrition, and bonding.

In January 2025, a JAMA Network Open study highlighted a worrying trend: antidepressant refills among pregnant women dropped by 50% compared to the year before pregnancy, yet psychotherapy usage didn't increase to fill the gap. This leaves a massive void in care. Guidelines uniformly advise against sudden stops. Instead, work with your doctor to adjust the dosage or switch to a safer alternative if needed. Withdrawal symptoms can also trigger stress responses in the body, which is counterproductive to a calm pregnancy.

Navigating the 2025 FDA Controversy

In July 2025, an FDA Expert Panel on SSRIs sparked intense debate. Some panelists raised alarms about potential risks, leading to immediate backlash from major medical organizations. ACOG President Steven J. Fleischman called the panel "alarmingly unbalanced," warning that it could incite fear and prevent patients from getting necessary treatment. Only one of ten panelists emphasized the critical role of SSRIs in preventing the devastating effects of untreated anxiety and depression.

This controversy highlights a communication gap between regulatory bodies and clinical practice. As a patient, don't let political or regulatory noise dictate your health choices. Trust the consensus of obstetricians and psychiatrists who treat you daily. The clinical evidence remains robust: for most women, the benefits of treating severe depression outweigh the minimal risks of SSRI exposure. Stay informed, but stay grounded in proven medical advice.

Your Action Plan for Safe Treatment

So, what should you actually do? First, never make changes to your medication regimen without consulting your healthcare provider. Second, aim for the lowest effective dose, especially during the first trimester when organ formation occurs. Third, consider a multidisciplinary approach. Combine medication with cognitive behavioral therapy (CBT) and regular exercise. This holistic strategy often allows for lower medication doses while maintaining mental stability.

Finally, keep open lines of communication between your OB-GYN and your psychiatrist. They need to share notes to ensure your treatment plan evolves as your pregnancy progresses. Remember, you are not choosing between yourself and your baby. By managing your mental health effectively, you are creating the safest possible foundation for both.